Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma

NCT01790737 is registered in ClinicalTrials.gov with Kuopio University Hospital as lead sponsor.

NCT NCT01790737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01790737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma
Lead sponsor
Kuopio University Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
February 26, 2019
Enrollment
80 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma